Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659429 | 1.00 | L3MBTL1 (0.50) | L3MBTL1MAPK1 | |
| SCHEMBL6663262 | 0.90 | DPP4 (0.54) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6663643 | 0.88 | NPBWR1 (0.55) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6663247 | 0.88 | NPBWR1 (0.55) | L3MBTL1 | |
| SCHEMBL6663904 | 0.88 | KMT2A (0.57) | L3MBTL1 | |
| SCHEMBL6905958 | 0.88 | KMT2A (0.57) | L3MBTL1 | |
| SCHEMBL6658081 | 0.86 | KDM4E (0.54) | L3MBTL1 | |
| SCHEMBL6658084 | 0.86 | KDM4E (0.54) | L3MBTL1 | |
| SCHEMBL27506526 | 0.86 | KDM4E (0.51) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6659280 | 0.85 | KDM4E (0.50) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257544-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMA (US) | 2012-07-25 | — | — | EP | disclosed |
| CN-1210274-C | Piperazine and piperidine derivatives | VERTEX PHARMA (US) | 2005-07-13 | — | — | CN | disclosed |
| US-20040034019-A1 | Piperazine and piperidine derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-19 | — | — | US | disclosed |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-10-09 | — | — | US | disclosed |
| CN-1404477-A | Piperazine and piperidine derivatives | VERTEX PHARMA (US) | 2003-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034019-A1 | Piperazine and piperidine derivatives | GAP43, BDNF, NGF | L3MBTL1 4374/4885MAPK1 1007/4885 |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | SREBF2, SREBF1, CYP46A1 | L3MBTL1 935/4885MAPK1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.